X

Drug Profile

Ritipenem acoxil

Alternative Names: FC/TA 891; FCE 22891; Penemac

Latest Information Update: 29 Aug 2006

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Pfizer; Tanabe Seiyaku
Class Antibacterials; Penems; Small molecules
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Bacterial infections

Most Recent Events

16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
06 Sep 1996 A study has been added to the therapeutic trials section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com